A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study ...

Johnson & Johnson has kicked off a marketing application in the US for TAR-200 as a treatment for a form of bladder cancer, using a novel technology that releases the drug intravesically ...

He highlighted recent FDA-approved treatments for BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC) and ongoing trials, such as the SunRISe-1 trial, which assess therapies like TAR ...

An expert discusses how TAR-200 shows promise for non–muscle invasive bladder cancer (NMIBC) treatment, with medical professionals optimistic about its targeted delivery, potentially improved outcomes ...

In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...

Bladder cancer affects approximately 83,000 Americans each year, yet remains one of the most overlooked forms of cancer despite having excellent survival rates when caught early. This disconnect ...

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle ...

Eddie Jordan died of bladder cancer on Thursday after being diagnosed with it last year. It's the eleventh most common cancer in the UK - yet doctors often say symptoms are overlooked. They've ...

The subtypes investigated in bladder cancer were CK19, CK20 and CK7 IHC/RT-PCR CK20: 56–46% [98,99]; CK7: 100% [99]; CK1: 93.1% [101] Association of CK19 with UPII detected pN0 patients with ...

Mar. 18, 2025 — Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor ...